5, 6 Of particular concern, the prevalence of CRKP has been sharply rising from 2.9–3% in 2005 to 25–26.3% in 2018 in China, and even reached 35.8% in neonatal patients. Carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a “critical concern” of the World Health Organization and poses great challenges for clinical treatment.
1 According to the global surveillance data, KP is the third leading bloodstream pathogen in children, and the frequency of antibiotic resistant KP has been increasing over years. Klebsiella pneumoniae (KP) has been implicated in severe infections and one of the most important causes of nosocomial infections.
0 kommentar(er)
